The Wolverine Stack: BPC-157 + TB-500 Research Guide
The Wolverine Stack pairs BPC-157 (10 mg) with TB-500 (5 mg), two widely researched recovery peptides studied for their complementary repair pathways. BPC-157 is investigated in preclinical models for localised tissue, tendon and gut repair plus angiogenesis, while TB-500 is studied for systemic cell migration and flexibility. It is supplied as a complete research kit for laboratory use only, not for human consumption.
What is the Wolverine Stack?
The Wolverine Stack is a recovery-focused research pairing of two peptides, BPC-157 (10 mg) and TB-500 (5 mg), studied together for their complementary tissue-repair pathways. It takes its nickname from the comic character known for rapid regeneration. BPC-157 is a synthetic pentadecapeptide investigated for localised repair of tendon, ligament and gut tissue and for angiogenesis, while TB-500 is a fragment of thymosin beta-4 researched for systemic cell migration and tissue flexibility. The pairing is one of the most discussed combinations in preclinical recovery literature.
The Wolverine Stack and every peptide referenced on this page are supplied strictly for in-vitro and laboratory research. Nothing here is intended for human or veterinary use, consumption, diagnosis, treatment or prevention of any condition. All statements describe published preclinical research, not outcomes in people.
At NovaPeptides the stack is supplied as a complete research kit rather than as loose vials, and every batch ships with a Novagen Laboratories Certificate of Analysis carrying a unique verification key. Researchers enquire by WhatsApp: there is no cart, no checkout and no price list.
Why BPC-157 and TB-500 are studied together
The two peptides are studied together because preclinical research associates them with different, complementary halves of the tissue-repair process. In these models, repair appears to involve both new blood-vessel formation and the migration of repair cells into damaged tissue. BPC-157 is investigated primarily for the first half, and TB-500 for the second, which is why researchers combine them in study designs rather than using either alone.
The complementary logic in brief
- BPC-157 is investigated for a role in angiogenesis, the growth of new blood vessels, through upregulation of VEGF and modulation of the nitric oxide (eNOS) pathway, and for localised repair of tendon, ligament and gut tissue.
- TB-500 is researched for its actin-binding activity, sequestering monomeric G-actin and supporting the cytoskeletal remodelling associated with cell migration, giving it a more systemic distribution profile in preclinical study.
- Together they are studied as a signal-plus-response pair: BPC-157 for the local growth-factor environment and vascular supply, TB-500 for mobilising and migrating the cells associated with repair.
- Their distinct mechanisms mean the pairing is described in the literature as mechanism-derived and complementary rather than redundant.
No published clinical trial has directly compared the BPC-157 + TB-500 pairing against either peptide used alone. The stacking rationale is drawn from separate preclinical mechanisms rather than head-to-head human outcome data. This is a research topic, not an established protocol.
BPC-157: localised repair and angiogenesis in research
BPC-157, short for Body Protection Compound-157, is a stable synthetic pentadecapeptide (15 amino acids) derived from a protective protein fraction identified in gastric juice. It has been characterised largely by the research group of Predrag Sikiric at the University of Zagreb across several decades of preclinical work. It is noted in the literature for its stability and for a structure that resists proteolytic breakdown.
In animal models it has been investigated for its association with tendon, ligament, muscle and gut tissue repair. Rat Achilles tendon transection studies reported faster functional and histological healing and improved collagen organisation versus saline controls. Mechanistically, BPC-157 has been studied for a role in upregulating VEGF and engaging the nitric-oxide (eNOS) system, a pathway associated in preclinical work with new blood-vessel formation and tissue perfusion. Its research profile is characteristically localised and cytoprotective.
TB-500: systemic cell migration and flexibility in research
TB-500 is a synthetic peptide corresponding to the active actin-binding region of thymosin beta-4, one of the more abundant proteins found in many cell types. Thymosin beta-4 binds monomeric G-actin in a roughly 1:1 ratio and acts as a regulator of actin availability, sequestering a share of the cellular G-actin pool. This actin-regulating activity is what makes it a compound of interest in cell-migration and cytoskeletal-remodelling research.
Because thymosin beta-4 is present throughout the body, TB-500 is often described in the literature as having a more systemic distribution than BPC-157. It has been investigated in tissue-repair, cardiac cell-survival and corneal epithelial-migration models, and is researched for an association with tissue flexibility and reduced scar-tissue formation. Where BPC-157 is studied for acting locally at a site of interest, TB-500 is researched for an association with repair processes across a wider area.
BPC-157 vs TB-500: comparison table
The two peptides are frequently confused because both appear in recovery research, but their origins, mechanisms and research profiles differ. This table summarises how they compare and why they are studied together in the Wolverine Stack.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Origin | Synthetic pentadecapeptide from a gastric-juice protein fraction | Synthetic fragment of thymosin beta-4 |
| Length | 15 amino acids | Short fragment of a 43-amino-acid protein |
| Primary mechanism studied | VEGF upregulation, eNOS / nitric-oxide angiogenesis | G-actin sequestration, cytoskeletal remodelling |
| Repair role researched | Localised tissue, tendon, ligament and gut repair | Systemic cell migration and flexibility |
| Distribution profile in research | Localised, cytoprotective | Systemic, whole-body |
| Content in this kit | 10 mg | 5 mg |
| Why studied together | Associated with growth-factor and vascular signalling | Associated with cell-migration response |
Both peptides are supplied for laboratory research only, not for human consumption. The attributes above describe mechanisms and findings reported in preclinical studies, not established effects in humans.
What the combined research suggests
Preclinical literature suggests the two peptides are associated with complementary stages of tissue repair. In animal tendon and wound models, studies have described enhanced collagen organisation and accelerated re-epithelialisation when repair-supporting peptides are present, with BPC-157 associated with angiogenesis around an injury zone and TB-500 associated with fibroblast and repair-cell migration into the damaged area. The combination is therefore studied as a way to examine both the vascular supply and the cellular response associated with repair.
Key points from the research base
- The stacking rationale is mechanism-derived: two different, non-overlapping repair pathways studied in the same models.
- BPC-157 has a substantial preclinical record relating to tendon, ligament and gut tissue; TB-500 has a preclinical record relating to cell migration and flexibility.
- Human clinical trial data for either peptide, and especially for the combination, remains limited in the published literature.
- No outcome percentage should be assumed for the pairing; claims of specific recovery figures are not supported by published head-to-head data.
The stacking logic for BPC-157 and TB-500 is mechanism-derived and drawn from preclinical models, not from clinical trials comparing the pairing to either peptide alone.
The Novagen Laboratories Certificate of Analysis
Every NovaPeptides batch ships with a Certificate of Analysis (COA) issued by Novagen Laboratories, an independent peptide and chemical research lab. The COA reports the identity and purity of the specific batch and carries a unique verification key, so a researcher can confirm the document is genuine rather than trusting a screenshot.
How COA verification works
- Locate the unique verification key printed on the COA.
- Copy the key and paste it into the verify field at novagenlaboratories.com.
- Novagen confirms whether the certificate is genuine, returned straight from the lab.
- You can request the batch COA over WhatsApp before enquiring further, with no obligation.
Batch-level analytical documentation with an independently verifiable key is a core expectation of responsible peptide research. It lets a lab confirm identity and purity for the exact batch received, rather than relying on a generic marketing claim.
How the Wolverine Stack is supplied
NovaPeptides supplies the Wolverine Stack as a complete research kit, not as a loose vial. The kit is built around a reusable dosing pen so measurement is consistent across a research protocol, and it arrives in protective packaging suitable for careful handling and storage.
| Kit component | Quantity |
|---|---|
| Aluminium reusable dosing pen | 1 |
| Bacteriostatic water | 1 |
| Peptide of choice (BPC-157 10 mg + TB-500 5 mg for this stack) | 1 stack |
| Needle heads | 5 |
| Extraction syringe | 1 |
| Thermal hard case | 1 |
To enquire, researchers message NovaPeptides on WhatsApp and state which kit they are after. There is no cart and no checkout maze. The batch Certificate of Analysis can be provided before ordering, with no obligation. Because this is a research-use-only catalogue, NovaPeptides does not provide dosing guidance or any personal-use instructions.
Researchers comparing recovery options often also look at the individual peptides, BPC-157 and TB-500 on their own, and at the broader KLOW blend. Each is supplied as a complete kit with its own Novagen COA and verification key.
Frequently asked questions
What is the Wolverine Stack?+
The Wolverine Stack is a recovery-focused research pairing of BPC-157 (10 mg) and TB-500 (5 mg), two widely researched recovery peptides. It is named after the comic character known for rapid regeneration. BPC-157 is studied in preclinical models for localised tissue, tendon and gut repair, while TB-500 is investigated for systemic cell migration and flexibility. It is supplied for laboratory research use only, not for human consumption.
Why are BPC-157 and TB-500 studied together?+
They are studied together because preclinical research associates them with complementary, non-overlapping halves of tissue repair. BPC-157 is investigated for angiogenesis and localised repair through VEGF and nitric-oxide pathways, while TB-500 is studied for cell migration through its actin-binding activity. Combining a growth-factor and vascular signal with a cell-migration response is the mechanism-derived rationale, though no clinical trial has compared the pairing to either peptide alone.
What is the difference between BPC-157 and TB-500?+
BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric-juice protein fraction, studied for localised repair of tendon, ligament and gut tissue and for angiogenesis. TB-500 is a fragment of thymosin beta-4 studied for systemic cell migration and flexibility through actin regulation. In short, BPC-157 is researched as a localised repair peptide and TB-500 as a more systemic one in preclinical work.
How much BPC-157 and TB-500 are in the Wolverine Stack?+
The NovaPeptides Wolverine Stack kit contains 10 mg of BPC-157 and 5 mg of TB-500. This is the pairing ratio commonly discussed in recovery research. Because the catalogue is research use only and not for human consumption, NovaPeptides does not provide dosing schedules, reconstitution volumes or any personal-use instructions.
Is the Wolverine Stack safe for humans?+
The Wolverine Stack is supplied strictly for in-vitro and laboratory research and is not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of any condition. Published data on both peptides comes largely from preclinical animal and cell studies, and human clinical trial evidence is limited. It should be handled only in an appropriate research setting.
What does the research say about the BPC-157 and TB-500 combination?+
Preclinical literature suggests the two peptides are associated with complementary repair stages, with BPC-157 associated with angiogenesis around an injury zone and TB-500 with repair-cell migration into damaged tissue. Animal studies have described enhanced collagen organisation and accelerated re-epithelialisation. However, no published clinical trial has compared the pairing to either peptide alone, so the rationale remains mechanism-derived rather than clinically established.
How is TB-500 studied to work?+
TB-500 corresponds to the active actin-binding region of thymosin beta-4, one of the more abundant proteins in many cell types. It binds monomeric G-actin in roughly a 1:1 ratio and is studied for regulating actin availability, supporting the cytoskeletal remodelling associated with cell migration. This actin-regulating activity is why it is a compound of interest in cell-migration, tissue-repair and cardiac cell-survival research.
How is BPC-157 studied to work?+
BPC-157 is a stable pentadecapeptide studied for cytoprotection and repair in preclinical models. It has been investigated for a role in upregulating VEGF and engaging the nitric-oxide (eNOS) pathway, a pathway associated with new blood-vessel formation and tissue perfusion. Its structure resists breakdown, and rat tendon-transection studies have reported improved collagen organisation and faster functional healing versus controls.
How is the Wolverine Stack supplied by NovaPeptides?+
It is supplied as a complete research kit rather than loose vials. Each kit includes an aluminium reusable dosing pen, bacteriostatic water, the peptide stack, five needle heads, an extraction syringe and a thermal hard case. Building the kit around a reusable pen supports consistent measurement across a research protocol. Everything is intended for laboratory use only, not for human consumption.
How do I verify the Novagen Laboratories COA?+
Every batch ships with a Novagen Laboratories Certificate of Analysis carrying a unique verification key. Copy that key, paste it into the verify field at novagenlaboratories.com, and Novagen confirms whether the certificate is genuine, straight from the lab. You can request the batch COA over WhatsApp before enquiring further, with no obligation.
How do I enquire about the Wolverine Stack in Australia?+
NovaPeptides takes enquiries through WhatsApp rather than a cart or checkout. Message the team, state which kit you are after, and the batch Certificate of Analysis can be provided before you order, with no obligation. Because the catalogue is research use only and not for human consumption, enquiries are handled for laboratory research purposes and no personal-use or dosing advice is provided.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp